Considerations for Defining Cytokine Dose, Duration, and Milieu That Are Appropriate for Modeling Chronic Low-Grade Inflammation in Type 2 Diabetes

<div>A flowchart of very basic differences in the pathophysiology of T1D and T2D. Each disease is described by the immune-mediated triggers, processes, and results with respect to the pancreatic beta-cell/islet.</div>

Journal of Diabetes Research

fig1

Figure 1

Figure 1: Considerations for Defining Cytokine Dose, Duration, and Milieu That Are Appropriate for Modeling Chronic Low-Grade Inflammation in Type 2 Diabetes 

Figure 1 | Considerations for Defining Cytokine Dose, Duration, and Milieu That Are Appropriate for Modeling Chronic Low-Grade Inflammation in Type 2 Diabetes 